Ketamine Therapy for Anxiety Disorders: What the Research Says and Who May Benefit

When Anxiety Persists Despite Standard Treatment

Anxiety disorders are among the most common mental health conditions in the United States. National survey data estimate that 19.1% of U.S. adults experienced an anxiety disorder in the past year, and anxiety can significantly interfere with work, relationships, and daily life (National Institute of Mental Health [NIMH], n.d.).

For some people, standard approaches such as therapy and medication do not bring adequate relief. At Soft Reboot Wellness in Menlo Park, California, we have seen growing interest from Bay Area patients—including professionals managing high-stakes careers while living with debilitating anxiety—in whether IV ketamine therapy might offer another clinical option.

What Research Says About Ketamine for Anxiety

The evidence base for ketamine in anxiety disorders is younger and smaller than the evidence base for depression, but it is growing. Systematic reviews have identified early evidence of anxiety symptom reduction following ketamine treatment in some anxiety-spectrum conditions, while also emphasizing the limited number of trials, small samples, and need for further research (Whittaker et al., 2021; Tully et al., 2022).

Published research has included patients with generalized anxiety disorder, social anxiety disorder, and anxiety symptoms occurring alongside depression. A small randomized trial in social anxiety disorder found greater symptom reduction following ketamine than placebo, but this was a proof-of-concept study rather than definitive evidence for broad clinical use (Taylor et al., 2018).

The mechanisms proposed to explain these effects overlap with those studied in depression: NMDA receptor antagonism, glutamate-related signaling, and downstream changes associated with synaptic plasticity (Abdallah et al., 2016). To understand more about the biological pathways involved, see our overview of the science behind ketamine therapy and its impact on mental health. The full relationship between these mechanisms and anxiety outcomes remains an active area of research.

What the Evidence Does and Does Not Support

It is essential to be transparent about what the evidence currently supports. IV ketamine for anxiety is used off-label, meaning it is not FDA-approved for anxiety disorders. Ketamine itself is FDA-approved as an anesthetic, while its psychiatric uses require individualized clinical judgment and informed consent (National Institute on Drug Abuse, 2024).

The clinical trials are promising but smaller and more preliminary than the depression literature, and the durability of anxiolytic effects from ketamine remains an important area of investigation (Whittaker et al., 2021; Tully et al., 2022).

At Soft Reboot Wellness, Dr. Sara Herman, MD discusses the current state of the evidence with each patient considering ketamine for anxiety—not to discourage treatment, but to ensure that the decision is fully informed. Genuine informed consent is a non-negotiable part of how we practice medicine. Patients who want to learn more about how ketamine compares to other pharmacological options can also explore our post on comparing ketamine versus SSRI treatment.

Anxiety in High-Pressure Environments

Many people seeking care for anxiety have managed their symptoms for years through a combination of therapy, medication, and sheer willpower. The productivity culture of Silicon Valley can create particular pressures for people living with health anxiety, social anxiety, perfectionism-driven generalized anxiety, or panic symptoms that have been carefully hidden from colleagues and sometimes from family.

When standard treatments have provided only partial relief, patients may begin considering interventional options and looking for information that is clinically grounded and honest about the limits of current research.

What an IV Ketamine Treatment Course May Involve

IV ketamine treatment at Soft Reboot Wellness is individualized. The number, timing, and pacing of sessions are determined through consultation, clinical response, treatment goals, and ongoing assessment rather than a fixed protocol for every patient.

During an infusion, patients may experience dissociation, visual or perceptual changes, and a dreamlike state. These effects are time-limited and monitored throughout the session. Dr. Herman personally administers and monitors treatments, with attention to both physiological safety and the patient’s experience.

Many anxiety patients find the anticipation of the infusion experience anxiety-provoking, which is understandable. Our team helps patients prepare for what to expect during ketamine therapy before their first session, including practical questions about the treatment environment, recovery period, and ride-home planning.

Considering Stellate Ganglion Block for Anxiety

Soft Reboot Wellness also offers Stellate Ganglion Block (SGB) as a separate interventional option for some patients experiencing anxiety, hyperarousal, chronic stress, or sympathetic nervous system dysregulation.

Not every patient is a candidate for ketamine, SGB, or a combined approach. Dr. Herman evaluates each person’s medical history, symptoms, medications, and treatment goals before making recommendations. The decision about whether an interventional approach is appropriate belongs in a thorough consultation, not in a blog post.

Cost, Preparation, and Ongoing Care

Two barriers deserve acknowledgment.

First, some anxiety patients are concerned that ketamine’s dissociative effects will feel anxiety-inducing rather than therapeutic. The experience can be uncomfortable for some people, particularly those with significant anticipatory anxiety. Preparation gives patients the opportunity to ask questions, understand what may occur, and decide whether treatment feels appropriate for them.

Second, cost matters. Insurance coverage for IV ketamine for psychiatric indications is inconsistent, and the out-of-pocket investment requires honest planning. We discuss pricing transparently from the beginning.

Results vary by individual, and we do not make promises about anxiety outcomes. What we offer is physician oversight, honest evidence communication, and individualized care for patients who are ready to explore their options. Please discuss with your provider whether IV ketamine therapy is appropriate for your anxiety profile before making treatment decisions.

FAQ

What types of anxiety disorders might benefit from IV ketamine?

Published research has included patients with generalized anxiety disorder, social anxiety disorder, and anxiety symptoms occurring alongside depression. The research base remains limited, and whether ketamine is appropriate for a specific anxiety diagnosis depends on your individual history and is assessed during consultation with Dr. Herman.

How rapidly does IV ketamine work for anxiety?

Some research has observed anxiety symptom changes within the first day after treatment, although response timing varies substantially between individuals (Whittaker et al., 2021; Taylor et al., 2018). Some people experience more gradual change over an initial series of infusions. Treatment is evaluated as a whole rather than based on the response to any single session.

Could ketamine make my anxiety worse?

The dissociative experience during an infusion can be uncomfortable for some people, especially those with strong anticipatory anxiety. A careful intake evaluation, discussion of expectations, and ongoing monitoring help determine whether treatment is appropriate for your situation.

How does IV ketamine for anxiety compare to benzodiazepines?

They are distinct medications with different mechanisms, risks, dosing patterns, and clinical roles. Ketamine is administered in discrete, supervised infusion sessions rather than as a daily medication. Do not stop, start, or change prescribed medication without guidance from the clinician managing your care.

Should I combine IV ketamine with therapy for anxiety?

Many patients choose to continue working with an existing therapist or psychiatrist while considering ketamine treatment. Soft Reboot Wellness can coordinate care with outside providers when appropriate and with your consent. Discuss with your provider how any new treatment may fit into your existing care plan.

Key Takeaways

• IV ketamine has a growing, though still developing, evidence base for anxiety disorders and anxiety-spectrum symptoms.
• Ketamine for anxiety is used off-label and is not FDA-approved for anxiety disorders.
• Soft Reboot Wellness in Menlo Park offers physician-led ketamine therapy under Dr. Sara Herman, MD, with individualized monitoring throughout treatment.
• Treatment planning, including the number and timing of infusions, is individualized rather than based on a single fixed protocol.
• Results vary by individual; preparation, coordination with existing providers, and transparent cost discussions are part of the consultation process.

Conclusion

Anxiety that persists despite standard treatment is not a character flaw. For some patients, it may be appropriate to explore additional options with a qualified medical provider.

At Soft Reboot Wellness in Menlo Park, we bring physician-led care, individualized evaluation, and transparent evidence communication to conversations about IV ketamine therapy for anxiety. If you are a Bay Area patient living with significant anxiety despite medications and therapy, discuss your options with your provider and contact our team to explore whether a consultation is appropriate.

References

Abdallah, C. G., Adams, T. G., Kelmendi, B., Esterlis, I., Sanacora, G., & Krystal, J. H. (2016). Ketamine’s mechanism of action: A path to rapid-acting antidepressants. Depression and Anxiety, 33(8), 689–697.

National Institute on Drug Abuse. (2024, April 9). Ketamine. https://nida.nih.gov/research-topics/ketamine

National Institute of Mental Health. (n.d.). Any anxiety disorder. https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder

Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., et al. (2018). Ketamine for social anxiety disorder: A randomized, placebo-controlled crossover trial. Neuropsychopharmacology, 43(2), 325–333. https://doi.org/10.1038/npp.2017.194

Tully, J. L., Dahlén, A. D., Haggarty, C. J., Schiöth, H. B., & Brooks, S. (2022). Ketamine treatment for refractory anxiety: A systematic review. British Journal of Clinical Pharmacology, 88(10), 4412–4426.

Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021). Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic Advances in Psychopharmacology, 11, 20451253211056743.

About Dr. Sara Herman

Dr. Sara Herman, MD, is a Harvard-trained, board-certified anesthesiologist and the founder of Soft Reboot Wellness. Her clinical experience in ketamine administration, pharmacology, and patient monitoring shapes each treatment plan, from dosing and preparation to physiological monitoring throughout the infusion experience.

At Soft Reboot Wellness, Dr. Herman provides a physician-led approach for patients exploring ketamine therapy, grounded in individualized assessment, informed consent, and evidence-informed care.

Medical Disclaimer

The content provided on this page is for educational purposes only and does not constitute medical advice. IV ketamine therapy for anxiety disorders is used off-label and is not FDA-approved for these indications. Individual results vary, and not every patient is an appropriate candidate. This information should not replace a consultation with a qualified medical provider. Please discuss with your provider whether any treatment described here is appropriate for your specific health situation. Soft Reboot Wellness serves patients in Menlo Park, CA and the greater Bay Area.